VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Cov19VaxKB
Host Responses
VaximmutorDB
VIGET
Vaxafe
Vaxar
Vaxism
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign2
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UM Logo

Vaccine Detail

SIV recombinant vector vaccine rAd5/rLCMV
Vaccine Information
  • Vaccine Name: SIV recombinant vector vaccine rAd5/rLCMV
  • Target Pathogen: Simian Immunodeficiency Virus
  • Target Disease: Simian AIDS
  • Vaccine Ontology ID: VO_0004564
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species as Laboratory Animal Model: Macaques
  • Antigen: a mismatched SIV envelope (Env) gene derived from simian immunodeficiency virus SIVmac239 (Flatz et al., 2012)
  • Vector:
  • Immunization Route: Intramuscular injection (i.m.)
Host Response

Macaque Response

  • Vaccine Immune Response Type: VO_0003057
  • Immune Response: Recombinant adenovirus type 5 (rAd5) prime followed by replication-defective lymphocytic choriomeningitis virus (rLCMV) boost elicited robust CD4 and CD8 T-cell and humoral immune responses. In addition, there was a presence of neutralizing antibodies to the challenge viruses tested in peripheral blood mononuclear cells (Flatz et al., 2012).
  • Efficacy: To evaluate the infectibility of immunized and control animals, 10 vaccinated Macaca mulatta animals and 10 controls were challenged intrarectally with SIVsmE660 six weeks after the rLCMV boost. In the vaccinated group, three of the 10 monkeys became infected after 99 challenges (3% infection rate per challenge), while in the control null group, eight of the 10 monkeys were infected after 47 challenges (17% infection rate per challenge), indicating a protective efficacy of 82% per challenge (Flatz et al., 2012).
References
Flatz et al., 2012: Flatz L, Cheng C, Wang L, Foulds KE, Ko SY, Kong WP, Roychoudhuri R, Shi W, Bao S, Todd JP, Asmal M, Shen L, Donaldson M, Schmidt SD, Gall JG, Pinschewer DD, Letvin NL, Rao S, Mascola JR, Roederer M, Nabel GJ. Gene-based vaccination with a mismatched envelope protects against simian immunodeficiency virus infection in nonhuman primates. Journal of virology. 2012; 86(15); 7760-7770. [PubMed: 22593152].